Literature DB >> 21765700

Influenza update 2000.

S A Kemmerly1.   

Abstract

Between 30,000-40,000 Americans die annually as a result of influenza epidemics. Spread primarily through the respiratory tract, influenza's classic signs and symptoms are the abrupt onset of fever, myalgia, headache, sore throat, malaise, and nonproductive cough. The elderly and patients with underlying medical illnesses may be at risk for secondary complications. Influenza is caused by an RNA myxovirus that exists in types A, B, and C; however, the A and B types are responsible for most human illness. The Centers for Disease Control and Prevention tracks the viruses' regular pathway through the US each year as they emerge first in Alaska and spread through the lower 48 states, peaking in activity during the winter months. Influenza is preventable by vaccination (efficacy 70%, depending on individual immune status) and is recommended for everyone at increased risk of complications from influenza between 6 months and 50 years of age, and universally for those over the age of 50. The composition of the vaccine has been changed for 2000-2001 to include two new type-A strains and one new type-B. Currently four drugs are available for the treatment of influenza. Early diagnosis can help reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. Bacterial infections can have similar symptoms or be complications of influenza and should be suspected and treated appropriately if present.

Entities:  

Year:  2000        PMID: 21765700      PMCID: PMC3117508     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  11 in total

1.  Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season. Advisory Committee on Immunization Practices.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-07-14       Impact factor: 17.586

2.  Update: Influenza activity--United States, 1999-2000 season.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-03-10       Impact factor: 17.586

3.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  C B Bridges; A G Winquist; K Fukuda; N J Cox; J A Singleton; R A Strikas
Journal:  MMWR Recomm Rep       Date:  2000-04-14

4.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

5.  Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.

Authors:  F G Hayden; R L Atmar; M Schilling; C Johnson; D Poretz; D Paar; L Huson; P Ward; R G Mills
Journal:  N Engl J Med       Date:  1999-10-28       Impact factor: 91.245

Review 6.  Serious morbidity and mortality associated with influenza epidemics.

Authors:  W P Glezen
Journal:  Epidemiol Rev       Date:  1982       Impact factor: 6.222

7.  Impact of epidemic type A influenza in a defined adult population.

Authors:  W H Barker; J P Mullooly
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

8.  Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.

Authors:  A S Monto; D P Robinson; M L Herlocher; J M Hinson; M J Elliott; A Crisp
Journal:  JAMA       Date:  1999-07-07       Impact factor: 56.272

9.  Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.

Authors:  M Schilling; L Povinelli; P Krause; M Gravenstein; A Ambrozaitis; H H Jones; P Drinka; P Shult; D Powers; S Gravenstein
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

Review 10.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

View more
  1 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2001-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.